Memantinforsterkning av målrettet kognitiv trening ved schizofreni
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Gregory A Light, Ph.D.
- Telefonnummer: 619-543-2496
- E-post: glight@health.ucsd.edu
Studer Kontakt Backup
- Navn: Joyce Sprock, B.A.
- Telefonnummer: 619-471-9455
- E-post: jsprock@health.ucsd.edu
Studiesteder
-
-
California
-
San Diego, California, Forente stater, 92103
- Clinical Teaching Facility (CTF B-403 at UCSD Medical Center)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Beskrivelse
Inklusjonskriterier:
- DSM-IV diagnose av schizofreni eller schizoaffektiv lidelse
- Skriftlig informert samtykke til å delta i studien
- Alder 18-65
- Fravær av demens eller psykisk utviklingshemming
- Urintoksikologi negativ for rekreasjonsmedisiner
- Flytende og kan engelsk
Ekskluderingskriterier:
- Oppfyller DSM-IV-kriteriene for nåværende rusmisbruk eller avhengighet og har vært rusavholdende i mindre enn 30 dager
- En historie med traumatisk hjerneskade
- Hørsels- eller synshemminger som er alvorlige nok til å hindre studiedeltakelse
- Under konservatorskap (bestemt av Anasazi)
- Svangerskap
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Placebo komparator: TCT + PBO
Forsøkspersoner vil bli tildelt placebo og vil fullføre 30 timer med målrettet kognitiv trening for å vurdere om memantin forbedrer kognitiv treningsytelse
|
Forsøkspersoner vil bli tildelt memantin eller placebo og vil fullføre 30 timer med målrettet kognitiv trening for å vurdere om memantin forbedrer kognitiv treningsytelse
Andre navn:
|
|
Aktiv komparator: TCT + MEM
Fagene vil bli tildelt memantin og vil fullføre 30 timer med målrettet kognitiv trening for å vurdere om memantin forbedrer kognitiv treningsytelse
|
Forsøkspersoner vil bli tildelt memantin eller placebo og vil fullføre 30 timer med målrettet kognitiv trening for å vurdere om memantin forbedrer kognitiv treningsytelse
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Positive & Negative Symptom Scale Total (PANSSt)
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
PANSS Total Score is the primary clinical outcome measured at baseline vs. post TCT session 10, 20 and 30 (approximately 16 weeks).
The PANSS total score has a range 30-210, with higher scores indicating worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
|
World Health Organization Disability Schedule (WHODAS 2.0)
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Function will be assessed via the World Health Organization Disability Schedule 2.0 (WHODAS 2.0) at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The World Health Organization Disability Schedule (WHODAS 2.0) has a range 12-60, with higher scores indicating worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
|
MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C)
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
The MCCB Global Composite T-score (MCCB-C) is the primary neurocognitive outcome measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The MATRICS Consensus Cognitive Battery (MCCB) composite T-score has no minimum or maximum score because it uses T-scores (e.g., 50 indicates the population mean with a standard deviation of 10), which are standardized based on a community sample.
A normal range MCCB composite T-score is between 40 and 60 and higher scores indicate better neurocognitive outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Positive & Negative Symptom Scale (PANSS) - Positive Symptom Subscale
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Positive & Negative Symptom Scale (PANSS) positive symptom subscale measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The PANSS positive symptom subscale is rated from 1 to 7 points ranging from absent to extreme.
The range for the Positive Symptom subscale is 7-49 and higher scores indicate worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
|
Positive & Negative Symptom Scale (PANSS) - Negative Symptom Subscale
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Positive & Negative Symptom Scale (PANSS) negative symptom subscale measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The PANSS negative symptom subscale is rated from 1 to 7 points ranging from absent to extreme.
The range for the negative symptom subscale is 7-49 and higher scores indicate worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
|
Psychotic Symptoms - PSYRATS Hallucination Subscale
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Psychotic Symptom Rating Scales (PSYRATS hallucination subscale) measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The PSYRATS auditory hallucinations subscale (AHS) consisting of 11 items, with each item being rated from 0 (absent) to 4 (severe), range 0-44, with higher scores indicating more severe auditory hallucinations or worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
|
Manic Symptoms - Young Mania Rating Scale
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Young Mania Rating Scale total score measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The range for the YMRS total score is 0-60, with higher scores indicating more severe manic symptoms or worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
|
Current Depressive Symptoms - PHQ-9
Tidsramme: Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Patient Health Questionnaire-9 (PHQ-9) total score measured at baseline vs. post-TCT session 10, 20 and 30 (approximately 16 weeks).
The PHQ-9 has a range from 0 to 27 with higher scores indicating more severe depression or worse outcome.
|
Baseline (at study enrollment), post-10 TCT sessions (approximately week 10), post-20 TCT sessions (approximately week 13) and post-30 TCT sessions (approximately week 16).
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 201502
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .